Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745800 | 0.95 | ALDH1A1 (0.36) | KDRKIF11ALDH1A1KDM4EKMT2A | |
| SCHEMBL4745799 | 0.88 | TOP2A (0.36) | ALDH1A1KMT2ATOP2A | |
| SCHEMBL4746335 | 0.82 | ALDH1A1 (0.39) | ALDH1A1KMT2ATOP2A | |
| SCHEMBL4745821 | 0.81 | PTGS1 (0.40) | ALDH1A1KMT2ATOP2A | |
| SCHEMBL4745857 | 0.81 | KDR (0.38) | KDRKIF11ALDH1A1KDM4EKMT2A | |
| SCHEMBL4746298 | 0.81 | PTPRC (0.38) | ALDH1A1KMT2ATOP2A | |
| SCHEMBL4746306 | 0.79 | PTGS1 (0.35) | ALDH1A1KMT2ATOP2A | |
| SCHEMBL4746300 | 0.79 | PTPRC (0.38) | ALDH1A1KMT2ATOP2A | |
| SCHEMBL4746287 | 0.77 | PTPRC (0.39) | ALDH1A1KMT2ATOP2A | |
| SCHEMBL4746454 | 0.76 | ALDH1A1 (0.40) | ALDH1A1KDM4EKMT2AMAPTTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | NR2E3, OR51E2, AZI2 | KDR 944/4885KIF11 3163/4885ALDH1A1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.